Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) treatment is challenging due to its dense tumor stroma.
• The sonic hedgehog (SHh) pathway drives desmoplasia, a key feature of PDAC stroma.
• Targeting cancer cell-stroma crosstalk is crucial for effective PDAC therapy.

Purpose of the Study:

• To investigate the efficacy of mesoporous silica nanoparticles (MSNs) for sequential drug delivery in PDAC.
• To evaluate the potential of MSNs loaded with an SHh inhibitor (cyclopamine) and chemotherapy drugs (Gemcitabine/cisplatin) for stroma modulation and PDAC treatment.
• To assess the therapeutic performance of this MSN-based delivery system in a preclinical mouse model.

Main Methods:

• Synthesis of two MSN-based drug delivery systems: CyP-MSNs (SHh inhibitor) and PEG-Gem-cisPt-MSNs (chemotherapy).
• In vitro and in vivo protein analysis to confirm SHh pathway inhibition by CyP-MSNs.
• Sequential administration of CyP-MSNs followed by PEG-Gem-cisPt-MSNs in HPAF II xenograft mice.

Main Results:

• CyP-MSNs effectively inhibited the SHh pathway.
• Sequential treatment led to significant stromal modulation in PDAC tumors.
• Improved accessibility of chemotherapy-loaded MSNs to the tumor site was observed.
• Enhanced therapeutic performance and reduced tumor progression in the xenograft mouse model.

Conclusions:

• MSN-based drug delivery systems show promise for modulating the tumor stroma in PDAC.
• Sequential delivery of SHh inhibitors and chemotherapy via MSNs can improve therapeutic outcomes.
• This approach offers a potential strategy to overcome treatment resistance and prevent pancreatic cancer progression.